Skip to main content
European Commission logo
italiano italiano
CORDIS - Risultati della ricerca dell’UE
CORDIS
CORDIS Web 30th anniversary CORDIS Web 30th anniversary

Gut OncoMicrobiome Signatures (GOMS) associated with cancer incidence, prognosis and prediction of treatment response.

Descrizione del progetto

Sfruttare il microbioma intestinale per la diagnosi e il trattamento del cancro

Un numero sempre maggiore di prove mette in evidenza il ruolo svolto dal microbioma intestinale nella salute e nelle malattie, tra cui il cancro. Lo scopo del progetto ONCOBIOME, finanziato dall’UE, è individuare e caratterizzare a livello funzionale i batteri commensali di elevata rilevanza clinica. Impiegando coorti costituite da più di 3 000 pazienti affetti da tumore in 10 diversi paesi, i partner del progetto individueranno le firme del microbioma relative all’insorgenza del cancro, alla sua prognosi e alla risposta alla terapia antitumorale. Inoltre, essi approfondiranno l’interazione meccanicistica con il metabolismo, l’immunità e l’oncogenesi dell’ospite. Oltre a fornire conoscenze fondamentali, i risultati del progetto porteranno a nuovi esami diagnostici e prognostici per il cancro, nonché a prebiotici e probiotici su misura.

Obiettivo

Beyond the role the intestinal metagenome plays in regulating multiple physBeyond its role in regulating multiple physiological functions that impact health, the intestinal metagenome is implicated in cancer initiation, progression and responses to therapies, even for extraintestinal neoplasia. Hence, there is an urgent need to fully identify and functionally characterize minimalist commensal ecosystems relevant to cancer, with reliable and robust methods, to validate cancer-associated gut microbiome fingerprints of high clinical relevance, and to develop diagnosis tools that will become part of the oncological arsenal for the optimization and personalization of therapy. Based on retro-and pro-spective studies, with large discovery and validation cohorts enrolling >9,000 cancer patients across 10 countries, ancillary to ongoing innovative clinical trials or FDA/EMA approvals across 4 frequent cancer types, ONCOBIOME will pursue the following aims: 1/ identify and validate core or cancer-specific Gut OncoMicrobiome Signatures (GOMS) associated with cancer occurrence, prognosis, response to, or progression on, therapy (polychemotherapy, immune checkpoint inhibitors, dendritic cell vaccines) or adverse effects, 2/ decipher the functional relevance of these cancer-associated gut commensal ecosystems in the regulation of host metabolism, immunity and oncogenesis, 3/ integrate these GOMS with other oncology hallmarks (clinics, genomics, immunomics, metabolomics) 4/ design optimal companion tests, based on those integrated signatures to predict cancer occurrence and progression. With high carat interdisciplinary experts, ONCOBIOME expects to validate cancer or therapy-specific Gut OncoMicrobiome Signatures (GOMS) across breast, colorectal, melanoma and lung cancers adjusting for covariates, to unravel the mode of action of these GOMS in innovative platforms, thus lending support to the design of cancer preventive campaigns using well characterized pre-and pro-biotics.

Invito a presentare proposte

H2020-SC1-BHC-2018-2020

Vedi altri progetti per questo bando

Bando secondario

H2020-SC1-2018-Single-Stage-RTD

Meccanismo di finanziamento

RIA - Research and Innovation action

Coordinatore

INSTITUT GUSTAVE ROUSSY
Contribution nette de l'UE
€ 2 792 214,75
Indirizzo
Rue Camille Desmoulins 39
94805 Villejuif
Francia

Mostra sulla mappa

Regione
Ile-de-France Ile-de-France Val-de-Marne
Tipo di attività
Research Organisations
Collegamenti
Costo totale
€ 2 942 214,75

Partecipanti (22)